Summary
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), modified so that it binds to the body's own albumin after injection and lasts far longer than the natural hormone, with a half-life of about eight days. Several listed suppliers also sell a product labelled 'CJC-1295 no DAC', which lacks that modification; it is a different molecule from the one in the trials below.
What it targets
A phase 1 study in healthy adults measured growth hormone and IGF-1 after administration and reported prolonged elevation of both. A second study asked whether continuous stimulation flattens the body's natural pulses of growth hormone, which are thought to matter for its effects: healthy men aged 20 to 40 were sampled every 20 minutes overnight before and a week after a single injection, and growth hormone secretion rose while the pulsatile pattern was preserved. Both studies are in healthy volunteers and measure hormone levels rather than any clinical outcome.
Clinical Research
Suppliers stocking CJC-1295
22 of the 30 listed suppliers. Each row opens its full listing.